372196-77-5 | PIK-75

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$23.00	$16.00
10mg	99%	in stock	$35.00	$24.00
25mg	99%	in stock	$62.00	$43.00

Description

• Catalog Number: AF68070
• Chemical Name: PIK-75
• CAS Number: 372196-77-5
• Molecular Formula: C16H14BrN5O4S
• Molecular Weight: 452.2825
• MDL Number: MFCD12546130
• SMILES: Brc1ccc2n(c1)cc(n2)/C=N/N(S(=O)(=O)c1cc(ccc1C)[N+](=O)[O-])C

Computed Properties

• Complexity: 679
• Covalently-Bonded Unit Count: 2
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4

Literature

• PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport.

  Molecular endocrinology (Baltimore, Md.) 20120801

• Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.

  The Biochemical journal 20120615

• Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.

  Journal of molecular endocrinology 20120601

• Characterization of molecular recognition of phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation.

  Journal of molecular modeling 20120501

• Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo.

  The Biochemical journal 20120215

• Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.

  Oncogene 20120209

• Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition.

  Molecular pharmacology 20111001

• Phosphatidylinositol 3-kinase isoform-specific effects in airway mesenchymal cell function.

  The Journal of pharmacology and experimental therapeutics 20110501

• Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.

  Bioorganic & medicinal chemistry 20070901